Huma Therapeutics, a global leader in healthcare AI driving digital transformation in care and research, announced two major strategic initiatives: a global partnership with healthcare growth equity firm Eckuity Capital and the acquisition of U.S.-based respiratory health company Aluna (also known as Knox Medical Diagnostics, Inc.). These developments aim to enhance Huma’s technology infrastructure and expand its capabilities in specialized disease management, particularly in respiratory care.

The partnership with Eckuity Capital is designed to support Huma’s aggressive M&A strategy and fuel its global expansion by providing resources to acquire complementary digital health companies. The collaboration focuses on launching and scaling digital solutions in healthcare and research, built on a solid regulatory foundation.

In parallel, the acquisition of Aluna significantly strengthens Huma’s offerings in respiratory disease management. Aluna, a leader in intelligent remote monitoring and respiratory device manufacturing, brings a network of over 150 U.S. health systems and clinics. Its proprietary peak flow meters and patient monitoring solutions will be relaunched on the Huma Cloud Platform, which features code-free configuration and AI/ML integration. This upgrade will elevate Aluna’s products to FDA Class II status and give its customers access to Huma’s broader suite of disease management programs for conditions like asthma, COPD, and sleep apnea, currently serving around 500,000 contracted lives.

These initiatives support Huma’s broader mission to build a comprehensive, disease-agnostic digital ecosystem. The company’s platform—already certified under FDA 510(k) Class II and EU MDR Class IIb—supports over 4,500 hospitals and clinics and reaches more than 50 million individuals across 70+ countries, contributing to national healthcare efforts in the U.S., U.K., Germany, Greece, and Saudi Arabia.

With over 25 million asthma and 15 million COPD patients in the U.S. alone, this expansion reinforces Huma’s leadership in chronic respiratory care. Aluna CEO Charvi Shetty highlighted the synergy, stating that integrating Aluna’s AI-driven technology with Huma’s platform creates a holistic digital health solution that empowers patients and clinicians worldwide in managing respiratory conditions more effectively.